Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse

Maria Fuller, Stephen Duplock, Christopher Turner, Philippa Davey, Doug A. Brooks, John J. Hopwood, Peter J. Meikle

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Glycogen storage in the α-glucosidase knockout (6neo/6neo) mouse recapitulates the biochemical defect that occurs in the human condition; as such, this mouse serves as a model for the inherited metabolic deficiency of lysosomal acid α-glucosidase known as Pompe disease. Although this model has been widely used for the assessment of therapies, the time course of glycogen accumulation that occurs as untreated Pompe mice age has not been reported. To address this, we developed a quantitative method involving amyloglucosidase digestion of glycogen and quantification of the resulting free glucose by liquid chromatography/electrospray ionization-tandem mass spectrometry. The method was sensitive enough to measure as little as 0.1 μg of glycogen in tissue extracts with intra- and interassay coefficients of variation of less than 12%. Quantification of glycogen in tissues from Pompe mice from birth to 26 weeks of age showed that, in addition to the accumulation of glycogen in the heart and skeletal muscle, glycogen also progressively accumulated in the brain, diaphragm, and skin. Glycogen storage was also evident at birth in these tissues. This method may be particularly useful for longitudinal assessment of glycogen reduction in response to experimental therapies being trialed in this model.

LanguageEnglish
Pages759-763
Number of pages5
JournalAnalytical Biochemistry
Volume421
Issue number2
DOIs
Publication statusPublished - 15 Feb 2012
Externally publishedYes

Keywords

  • Glycogen
  • Mass spectrometry
  • Mouse
  • Pompe disease

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Fuller, M., Duplock, S., Turner, C., Davey, P., Brooks, D. A., Hopwood, J. J., & Meikle, P. J. (2012). Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse. Analytical Biochemistry, 421(2), 759-763. https://doi.org/10.1016/j.ab.2011.12.026
Fuller, Maria ; Duplock, Stephen ; Turner, Christopher ; Davey, Philippa ; Brooks, Doug A. ; Hopwood, John J. ; Meikle, Peter J. / Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse. In: Analytical Biochemistry. 2012 ; Vol. 421, No. 2. pp. 759-763.
@article{c102f963285d4bcb904666e96ba83d28,
title = "Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse",
abstract = "Glycogen storage in the α-glucosidase knockout (6neo/6neo) mouse recapitulates the biochemical defect that occurs in the human condition; as such, this mouse serves as a model for the inherited metabolic deficiency of lysosomal acid α-glucosidase known as Pompe disease. Although this model has been widely used for the assessment of therapies, the time course of glycogen accumulation that occurs as untreated Pompe mice age has not been reported. To address this, we developed a quantitative method involving amyloglucosidase digestion of glycogen and quantification of the resulting free glucose by liquid chromatography/electrospray ionization-tandem mass spectrometry. The method was sensitive enough to measure as little as 0.1 μg of glycogen in tissue extracts with intra- and interassay coefficients of variation of less than 12{\%}. Quantification of glycogen in tissues from Pompe mice from birth to 26 weeks of age showed that, in addition to the accumulation of glycogen in the heart and skeletal muscle, glycogen also progressively accumulated in the brain, diaphragm, and skin. Glycogen storage was also evident at birth in these tissues. This method may be particularly useful for longitudinal assessment of glycogen reduction in response to experimental therapies being trialed in this model.",
keywords = "Glycogen, Mass spectrometry, Mouse, Pompe disease",
author = "Maria Fuller and Stephen Duplock and Christopher Turner and Philippa Davey and Brooks, {Doug A.} and Hopwood, {John J.} and Meikle, {Peter J.}",
year = "2012",
month = "2",
day = "15",
doi = "10.1016/j.ab.2011.12.026",
language = "English",
volume = "421",
pages = "759--763",
journal = "Analytical Biochemistry",
issn = "0003-2697",
publisher = "Academic Press Inc.",
number = "2",

}

Fuller, M, Duplock, S, Turner, C, Davey, P, Brooks, DA, Hopwood, JJ & Meikle, PJ 2012, 'Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse', Analytical Biochemistry, vol. 421, no. 2, pp. 759-763. https://doi.org/10.1016/j.ab.2011.12.026

Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse. / Fuller, Maria; Duplock, Stephen; Turner, Christopher; Davey, Philippa; Brooks, Doug A.; Hopwood, John J.; Meikle, Peter J.

In: Analytical Biochemistry, Vol. 421, No. 2, 15.02.2012, p. 759-763.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse

AU - Fuller, Maria

AU - Duplock, Stephen

AU - Turner, Christopher

AU - Davey, Philippa

AU - Brooks, Doug A.

AU - Hopwood, John J.

AU - Meikle, Peter J.

PY - 2012/2/15

Y1 - 2012/2/15

N2 - Glycogen storage in the α-glucosidase knockout (6neo/6neo) mouse recapitulates the biochemical defect that occurs in the human condition; as such, this mouse serves as a model for the inherited metabolic deficiency of lysosomal acid α-glucosidase known as Pompe disease. Although this model has been widely used for the assessment of therapies, the time course of glycogen accumulation that occurs as untreated Pompe mice age has not been reported. To address this, we developed a quantitative method involving amyloglucosidase digestion of glycogen and quantification of the resulting free glucose by liquid chromatography/electrospray ionization-tandem mass spectrometry. The method was sensitive enough to measure as little as 0.1 μg of glycogen in tissue extracts with intra- and interassay coefficients of variation of less than 12%. Quantification of glycogen in tissues from Pompe mice from birth to 26 weeks of age showed that, in addition to the accumulation of glycogen in the heart and skeletal muscle, glycogen also progressively accumulated in the brain, diaphragm, and skin. Glycogen storage was also evident at birth in these tissues. This method may be particularly useful for longitudinal assessment of glycogen reduction in response to experimental therapies being trialed in this model.

AB - Glycogen storage in the α-glucosidase knockout (6neo/6neo) mouse recapitulates the biochemical defect that occurs in the human condition; as such, this mouse serves as a model for the inherited metabolic deficiency of lysosomal acid α-glucosidase known as Pompe disease. Although this model has been widely used for the assessment of therapies, the time course of glycogen accumulation that occurs as untreated Pompe mice age has not been reported. To address this, we developed a quantitative method involving amyloglucosidase digestion of glycogen and quantification of the resulting free glucose by liquid chromatography/electrospray ionization-tandem mass spectrometry. The method was sensitive enough to measure as little as 0.1 μg of glycogen in tissue extracts with intra- and interassay coefficients of variation of less than 12%. Quantification of glycogen in tissues from Pompe mice from birth to 26 weeks of age showed that, in addition to the accumulation of glycogen in the heart and skeletal muscle, glycogen also progressively accumulated in the brain, diaphragm, and skin. Glycogen storage was also evident at birth in these tissues. This method may be particularly useful for longitudinal assessment of glycogen reduction in response to experimental therapies being trialed in this model.

KW - Glycogen

KW - Mass spectrometry

KW - Mouse

KW - Pompe disease

UR - http://www.scopus.com/inward/record.url?scp=84859733901&partnerID=8YFLogxK

U2 - 10.1016/j.ab.2011.12.026

DO - 10.1016/j.ab.2011.12.026

M3 - Article

VL - 421

SP - 759

EP - 763

JO - Analytical Biochemistry

T2 - Analytical Biochemistry

JF - Analytical Biochemistry

SN - 0003-2697

IS - 2

ER -